New hope has emerged for people with diabetes (diabetes) in Indonesia, especially those on medication but had not a significant improvement.
Now, has come a new generation of drugs berzat active Vildagliptin, who claimed to have advantages over groups or generations.
GalviusGambar: Galvus (vildagliptin) is an oral drug taken once a day for patients with type 2 diabetes. Vildagliptin works by increasing the amount of two hormones inkretin found in the body called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Chairman of the Endocrinology Society of Indonesia (Perkeni), Dr. Soewondo Sp.PD Pradana-KEMD, stated, Vildagliptin is an oral diabetes medicine that uses a new approach.
"So far, the treatment of diabetes only for insulin (a hormone that lowers blood glucose levels), whereas glukagonnya (which increases blood glucose levels) have not been touched," said Suwondo Media Education in the Diabetes Management in Jakarta, Thursday (16/10).
Vildagliptin acts as an inhibitor of protein Dipeptidyl peptidase-4 (DPP-4 INH) are potent, selective and reversible. Simply put, this drug works by improving the function of pancreatic beta cells (cells that produce insulin) and pankeras alpha cells (which produce glucagon) as well as improve insulin sensitivity.
Inkretin
According Soewondo, other than lack of insulin, diabetes was also inkretin hormone deficiency, a type of hormone secreted intestinal tract when the food comes in, serves to regulate and control blood glucose. Inkretin also play a role in improving the function of the balance between glucagon and insulin.
Lack inkretin caused by the presence of DPP-4 protein that works to break inkretin. In fact, the lack of this hormone can interfere inkretin balance between glucagon and insulin.
"With the presence of inhibitors (inhibitors) DPP-4, the balance will be achieved so that the function of any organ of the pancreas will increase," said Suwondo.
Vildagliptin, he added, also produce effects farmakologik improve beta cell function is damaged and the only thing that worked against the alpha cells. The results of clinical trials indicate, patients who received vildagliptin 50 mg one tablet daily, beta cells more sensitive to glucose than not.
"In other words, Valdigliptin able to improve the function of improving the sensitivity of pancreatic secretion of glucagon on glucose and improve insulin sensitivity of glucose secretion," he said.
Vildagliptin will be marketed PT Dexa Medica October 2008 with effect from this. This drug was discovered by Novartis, the pharmaceutical company based in Switzerland, but in Indonesia this drug will be marketed by Dexa Medica.
"Novartis and Dexa Medica conduct competency sharing to market these drugs to consumers in Indonesia. Socialization and introduction to the doctors will be conducted this week in 6 major cities, "said Head Marketing and Sales Synergy Dexa Medica, Dorothy Mary Dharma.
Source: Kompas.com | October 16, 2008 Posted by. Rudi
